BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, the leading biotechnology company in the field of epitope shielding, presented data for its CD45 and CD33 programs during ...
CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its CD45 Shielded Cell & ...
Because CD45 is found on nearly all blood cells -- and is usually highly expressed on blood cancer cells -- a treatment that wipes out all CD45-bearing cells would leave patients without any blood ...
CD45 + C1q + CCR8+ cells may serve as a biomarker for kidney disease severity and progression risk, reflecting inflammation and fibrosis. Elevated levels of these cells correlate with serum creatinine ...
CAR-T cell therapies have been heralded as a game changer for blood cancers, but those therapies approved so far have been focused on a few subtypes of leukemia, lymphoma and myeloma. Now, a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results